Nasdaq

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine ...

Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...
ascopubs.org

A phase II study of an oncolytic herpes simplex virus 2 and an anti-PD-1 antibody in patients with advanced sarcoma.

Analyzing the effect of treatment modalities on survival in synovial sarcoma. Maintenance treatment with toripalimab and anlotinib after anthracycline-based chemotherapy in patients with advanced soft ...
Seeking Alpha

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – – Phase 1b study portion of multiple ...
Seeking Alpha

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI ...

– Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly ...